FindTrial
Sign In

Finding the best way to stop atropine eye drops to minimize rebound myopia: A study on slow, very slow, and sudden cessation of atropine eye drops with lifestyle changes.

A Randomized Controlled Trial of Gradual (Slow Versus Very Slow) Versus Sudden Cessation of Atropine Therapy and Monitored Lifestyle Changes in the Incidence and Magnitude of Rebound Myopia. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063869
Enrollment
50
Registered
2024-03-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H521- Myopia

Interventions

Intervention1: Tapering of atropine eye drop in high myopic eye.: For Group A, in high myopic or dominant eye, atropine eye drop will be tapered over 7 months (one day per week per month). For Group B

Sponsors

Sneha Jain
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Magnitude of myopia at least -1D in each eye. Astigmatism less than 4.5D in each eye. Documented nonprogressive myopia i.e. 0D and axial length progression less than 0.2mm per year. Children who are on atropine eye drop therapy at any frequency and various concentration

Exclusion criteria

Exclusion criteria: Allergic to atropine. Any comorbidities systemic as well as ocular Children who have pathological myopia BCVA less than 20 by 40 and 6 by 24 Axial length more than 26.5mm OCT macula abnormal

Design outcomes

Primary

MeasureTime frame
Myopia in diopter (sphere)Timepoint: 13 months—

Secondary

MeasureTime frame
Axial length in mmTimepoint: 13 months—

Countries

India

Contacts

Public ContactVishram Sangit

Jupiter Hospital

drmihirkothari@gmail.com93204037173

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026